Study Offers Support For Biosimilar-To-Biosimilar Switching
Practice Is Safe And Effective, But Not Covered By Current Regulations Or Guidance
A new paper has examined the issue of biosimilar-to-biosimilar switching, concluding that it is a safe and effective clinical practice but highlighting a lack of current health authority regulations or guidance on the subject.
You may also be interested in...
A science-based approach to biosimilars, exemplified by the latest statement from European regulators, makes further progress on biosimilars just a matter of time, according to Gillian Woollett, vice president and head of regulatory strategy and policy at Samsung Bioepis.
In the wake of a recent paper which concluded that moving patients between two different biosimilar versions of the same brand biologic was safe and effective, Generics Bulletin speaks to Sandoz Inc executive director of scientific affairs Hillel Cohen about the growing importance of – and challenges to – biosimilar-to-biosimilar switching.
Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.